Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Syndax Pharmaceuticals ( (SNDX) ) has shared an update.
Syndax Pharmaceuticals has announced the elimination of the Chief Medical Officer position, resulting in Catherine Madigan, M.D. departing from the company. This organizational change may impact Syndax’s operational dynamics, signaling potential shifts in their strategic focus or cost management efforts.
More about Syndax Pharmaceuticals
Syndax Pharmaceuticals operates in the biotechnology industry, focusing on developing therapies for cancer treatment.
YTD Price Performance: -40.54%
Average Trading Volume: 1,647,199
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.1B
For a thorough assessment of SNDX stock, go to TipRanks’ Stock Analysis page.
